blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3319982

EP3319982 - NEW EXENDIN-4 DERIVATIVES AS SELECTIVE PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.01.2021
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  24.01.2020
FormerGrant of patent is intended
Status updated on  22.10.2019
FormerExamination is in progress
Status updated on  19.07.2019
FormerRequest for examination was made
Status updated on  13.04.2018
FormerThe international publication has been made
Status updated on  20.01.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
SANOFI
54, rue La Boétie
75008 Paris / FR
[2018/20]
Inventor(s)01 / BOSSART, Martin
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
02 / EVERS, Andreas
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
03 / HAACK, Torsten
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
04 / LORENZ, Katrin
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
05 / KADEREIT, Dieter
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
06 / WAGNER, Michael
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
07 / HENKEL, Bernd
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
 [2018/20]
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[2018/20]
Application number, filing date16738403.108.07.2016
[2018/20]
WO2016EP66299
Priority number, dateEP2015030614110.07.2015         Original published format: EP 15306141
[2018/20]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2017009236
Date:19.01.2017
Language:EN
[2017/03]
Type: A2 Application without search report 
No.:EP3319982
Date:16.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 19.01.2017 takes the place of the publication of the European patent application.
[2018/20]
Type: B1 Patent specification 
No.:EP3319982
Date:26.02.2020
Language:EN
[2020/09]
Search report(s)International search report - published on:EP16.02.2017
ClassificationIPC:C07K14/435
[2018/20]
CPC:
C07K14/605 (EP,KR,US); A61K38/26 (EP,KR,US); A61K45/06 (KR,US);
A61P1/16 (EP); A61P3/00 (EP,KR); A61P3/04 (EP);
A61P3/10 (EP); A61P43/00 (EP); A61P9/00 (EP,KR);
A61P9/10 (EP); A61P9/12 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/20]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:NEUE EXENDIN-4-DERIVATE ALS SELEKTIVE PEPTIDISCHE DUALE GLP-1/GLUCAGON-REZEPTORAGONISTEN[2018/20]
English:NEW EXENDIN-4 DERIVATIVES AS SELECTIVE PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS[2018/20]
French:NOUVEAUX DÉRIVÉS D'EXENDIN-4 UTILISÉS COMME AGONISTES DU RÉCEPTEUR DU GLUCAGON/GLP-1 DOUBLE[2019/42]
Former [2018/20]NOUVEAUX DÉRIVÉS D'EXENDINE-4 UTILISÉS EN TANT QU'AGONISTES PEPTIDIQUES DOUBLES DES RÉCEPTEURS DU GLP1/GLUCAGON
Entry into regional phase12.02.2018National basic fee paid 
12.02.2018Designation fee(s) paid 
12.02.2018Examination fee paid 
Examination procedure25.01.2018Amendment by applicant (claims and/or description)
25.01.2018Date on which the examining division has become responsible
12.02.2018Examination requested  [2018/20]
24.07.2019Despatch of a communication from the examining division (Time limit: M04)
03.09.2019Reply to a communication from the examining division
23.10.2019Communication of intention to grant the patent
15.01.2020Fee for grant paid
15.01.2020Fee for publishing/printing paid
15.01.2020Receipt of the translation of the claim(s)
Opposition(s)27.11.2020No opposition filed within time limit [2021/05]
Fees paidRenewal fee
11.07.2018Renewal fee patent year 03
15.07.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.07.2016
AL26.02.2020
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MK26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
IE08.07.2020
LU08.07.2020
PT19.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
[2022/31]
Former [2022/30]HU08.07.2016
AL26.02.2020
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
IE08.07.2020
LU08.07.2020
PT19.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
Former [2022/27]HU08.07.2016
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
IE08.07.2020
LU08.07.2020
PT19.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
Former [2021/37]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
IE08.07.2020
LU08.07.2020
PT19.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
Former [2021/24]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
LU08.07.2020
PT19.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
Former [2021/20]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
LU08.07.2020
PT19.07.2020
CH31.07.2020
LI31.07.2020
Former [2021/13]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2021/10]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/50]CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/49]CZ26.02.2020
DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/48]DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/47]DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/45]FI26.02.2020
HR26.02.2020
LV26.02.2020
NL26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/40]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/39]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
Former [2020/38]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
NO26.05.2020
GR27.05.2020
Former [2020/37]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
NO26.05.2020
Former [2020/35]FI26.02.2020
NO26.05.2020
Cited inInternational search[A]WO2007139941  (AMYLIN PHARMACEUTICALS INC [US], et al) [A] 1-41 * claim 18; sequence 21 * * page 45, line 29 - page 4, line 16 *;
 [A]WO2011000095  (ANGIOCHEM INC [CA], et al) [A] 1-41 * page 4, line 33 * * page 47, line 7 - line 8 *;
 [A]WO2011024110  (RINAT NEUROSCIENCE CORP [US], et al) [A] 1-41 * figure 1 *;
 [A]WO2013093720  (PFIZER [US], et al) [A] 1-41 * page 48, line 8 - line 25; sequence 53 *;
 [A]US2013336893  (HAACK TORSTEN [DE], et al) [A] 1-41 * page 2, line 25 - line 29; claim 1; sequence 4 * * paragraph [0238] - paragraph [0262]; claim 33 *;
 [A]WO2014081872  (MEDERIS DIABETES LLC [US]) [A] 1-41 * figure 1; claim 1 * * paragraph [0240] - paragraph [0241] *;
 [A]WO2015086731  (SANOFI SA [FR]) [A] 1-41 * claim 1; sequence 4 * * page 27, line 16 - page 31, line 26; claim 15 *;
 [I]WO2015100876  (ADLAI NORTYE PHARMACEUTICAL CO LTD [CN]) [I] 42 * abstract *;
 [A]  - DAY JONATHAN W ET AL, "A new glucagon and GLP-1 co-agonist eliminates obesity in rodents", NATURE CHEMICAL BIOLOGY, NATURE PUB. GROUP, GB, vol. 5, no. 10, doi:10.1038/NCHEMBIO.209, ISSN 1552-4450, (20091001), pages 749 - 757, (20090713), XP002558889 [A] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1038/nchembio.209
 [A]  - MEIER JJ ET AL, "Incretin-based therapies: where will we be 50 years from now?", vol. 58, ISSN 1432-0428, (20150521), pages 1745 - 1750, INTERNET CITATION, URL: http://rd.springer.com/article/10.1007%2Fs00125-015-3608-6, (20150811), XP002743286 [A] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00125-015-3608-6pubmed:25994073
 [A]  - LORENZ MARTIN ET AL, "Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20130516), vol. 23, no. 14, doi:10.1016/J.BMCL.2013.05.022, ISSN 0960-894X, pages 4011 - 4018, XP028573319 [A] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2013.05.022
 [A]  - BRIAN P. WARD ET AL, "Peptide lipidation stabilizes structure to enhance biological function", MOLECULAR METABOLISM, (20131101), vol. 2, no. 4, doi:10.1016/j.molmet.2013.08.008, ISSN 2212-8778, pages 468 - 479, XP055323657 [A] 42 * abstract * * page 468, column r, paragraph 2 - page 469, column l2 *

DOI:   http://dx.doi.org/10.1016/j.molmet.2013.08.008
 [A]  - KNUDSEN LOTTE B ET AL, "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20000504), vol. 43, no. 9, doi:10.1021/JM9909645, ISSN 0022-2623, pages 1664 - 1669, XP002201014 [A] 42 * abstract * * page 1665, column l, paragraph 1 * * page 1667, column l, paragraph last - page 1668, column l *

DOI:   http://dx.doi.org/10.1021/jm9909645
 [IP]  - GURYANOV IVAN ET AL, "Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide", PROTEIN TRANS-SPLICING ON AN M13 BACTERIOPHAGE: TOWARDS DIRECTED EVOLUTION OF A SEMISYNTHETIC SPLIT INTEIN BY PHAGE DISPLAY, JOURNAL OF PEPTIDE SCIENCE, VOL. 16, NR. 10, SP. ISS. SI, PAGE(S) 575-581, (20160701), vol. 22, no. 7, ISSN 1075-2617, pages 471 - 479, XP002761314 [IP] 42 * abstract * * page 471, column r, line 3 - page 473, column l, line 15; figure 1; table 1 * * Scheme 1 *

DOI:   http://dx.doi.org/10.1002/psc.2890
 [AP]  - LAU JESPER ET AL, "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide", JOURNAL OF MEDICINAL CHEMISTRY, (201509), vol. 58, no. 18, pages 7370 - 7380, XP002764741 [AP] 42 * abstract *

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.5b00726
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.